GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Mangoceuticals Inc (NAS:MGRX) » Definitions » EV-to-EBITDA

Mangoceuticals (Mangoceuticals) EV-to-EBITDA : -1.16 (As of May. 28, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mangoceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Mangoceuticals's enterprise value is $10.39 Mil. Mangoceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.00 Mil. Therefore, Mangoceuticals's EV-to-EBITDA for today is -1.16.

The historical rank and industry rank for Mangoceuticals's EV-to-EBITDA or its related term are showing as below:

MGRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.76   Med: -1.34   Max: -0.31
Current: -1.16

During the past 3 years, the highest EV-to-EBITDA of Mangoceuticals was -0.31. The lowest was -18.76. And the median was -1.34.

MGRX's EV-to-EBITDA is ranked worse than
100% of 465 companies
in the Healthcare Providers & Services industry
Industry Median: 12.65 vs MGRX: -1.16

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-28), Mangoceuticals's stock price is $0.4112. Mangoceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.470. Therefore, Mangoceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Mangoceuticals EV-to-EBITDA Historical Data

The historical data trend for Mangoceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mangoceuticals EV-to-EBITDA Chart

Mangoceuticals Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBITDA
- - -0.58

Mangoceuticals Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.07 -4.28 -1.81 -0.58 -0.59

Competitive Comparison of Mangoceuticals's EV-to-EBITDA

For the Health Information Services subindustry, Mangoceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mangoceuticals's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Mangoceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Mangoceuticals's EV-to-EBITDA falls into.



Mangoceuticals EV-to-EBITDA Calculation

Mangoceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=10.391/-8.995
=-1.16

Mangoceuticals's current Enterprise Value is $10.39 Mil.
Mangoceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mangoceuticals  (NAS:MGRX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Mangoceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.4112/-0.470
=At Loss

Mangoceuticals's share price for today is $0.4112.
Mangoceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.470.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Mangoceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Mangoceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Mangoceuticals (Mangoceuticals) Business Description

Traded in Other Exchanges
N/A
Address
15110 N. Dallas Parkway, Suite 600, Dallas, TX, USA, 75248
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED product.
Executives
Amanda Elizabeth Hammer officer: Chief Operating Officer 5128 GADSDEN AVENUE, KELLER TX 76244
Jacob D. Cohen director, 10 percent owner, officer: CEO 2101 GLENDALE DRIVE, PLANO TX 75023
Tiger Cub Trust 10 percent owner 19 RYDDINGTON PL, DALLAS TX 75230
Kenny Myers director 5101 ADDISON CIRCLE,, UNIT 401,, ADDISON TX 75001
Lorraine Pamela D'alessio director 8200 WILSHIRE BLVD, BEVERLY HILLS, CALIFORNIA CA 90211
Eugene M Johnston officer: CFO PO BOX 669047, CHARLOTTE NC 28266
Jonathan Arango director, officer: President, COO and Secretary 15110 DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Alex P. Hamilton director 26 LOOP ROAD, BEDFORD NY 10506

Mangoceuticals (Mangoceuticals) Headlines